EODData

MEMBERSHIP REGISTER LOG IN

PAR, GNFT: Genfit S.A.

08 Oct 2025
LAST:

3.454

CHANGE:
 0.03		OPEN:
3.416		HIGH:
3.504		ASK:
23.490		VOLUME:
136K
CHG(%):
0.82		PREV:
3.426		LOW:
3.404		BID:
23.050		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
08 Oct 253.4163.5043.4043.454136K
07 Oct 253.4103.4303.3703.42678.6K
06 Oct 253.4823.5743.3403.418348.5K
03 Oct 253.5003.5683.4403.500264.5K
02 Oct 253.4343.5083.4043.500310.4K
01 Oct 253.3003.4063.2303.374326.6K
30 Sep 253.1783.2783.1703.272217.8K
29 Sep 253.1463.2143.1303.160310.5K
26 Sep 253.0703.1523.0623.130146.4K
25 Sep 253.1003.1743.0503.050254.7K

COMPANY PROFILE

Name:Genfit S.A.
About:Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
Sector:Healthcare
Industry:Biotechnology
Address:Parc EurasantE, Loos, France, 59120
Website:https://www.genfit.com
ISIN:FR0004163111

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:115.67
EPS Ratio:-0.78
Price to Book:3.10
Price to Sales:2.57
EBITDA:4.69M
Shares:50M
Market Cap:172.71M

TECHNICAL INDICATORS

MA5:3.46
MA10:3.33
MA20:3.43
MA50:3.49
MA100:3.49
MA200:3.51
STO9:72.97
STO14:58.89
RSI14:44.68
WPR14:-33.11
MTM14:-0.20
ROC14:-0.05
ATR:0.15
Week High:3.57
Week Low:3.23
Month High:3.74
Month Low:3.05
Year High:5.86
Year Low:2.62

RECENT SPLITS

Date Ratio
12 Oct 20161739-1687
09 Jan 20141077-1067